Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

A pair of newly developed models may help better predict outcomes in patients with diffuse large B-cell lymphoma (DLBCL). The ...

In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...

Please provide your email address to receive an email when new articles are posted on . Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

– Application is based on data from the Phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival – – This ...